ES2525029T3 - Predicción del riesgo de sufrir episodios cardíacos adversos graves - Google Patents

Predicción del riesgo de sufrir episodios cardíacos adversos graves Download PDF

Info

Publication number
ES2525029T3
ES2525029T3 ES13179055.2T ES13179055T ES2525029T3 ES 2525029 T3 ES2525029 T3 ES 2525029T3 ES 13179055 T ES13179055 T ES 13179055T ES 2525029 T3 ES2525029 T3 ES 2525029T3
Authority
ES
Spain
Prior art keywords
macers
subject
treatment
risk
compared
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13179055.2T
Other languages
English (en)
Spanish (es)
Inventor
James V. Snider
Eugene R. Heyman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Critical Care Diagnostics Inc
Original Assignee
Critical Care Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Critical Care Diagnostics Inc filed Critical Critical Care Diagnostics Inc
Application granted granted Critical
Publication of ES2525029T3 publication Critical patent/ES2525029T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Electrotherapy Devices (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
ES13179055.2T 2008-04-18 2009-04-17 Predicción del riesgo de sufrir episodios cardíacos adversos graves Active ES2525029T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4615808P 2008-04-18 2008-04-18
US46158P 2008-04-18

Publications (1)

Publication Number Publication Date
ES2525029T3 true ES2525029T3 (es) 2014-12-16

Family

ID=41199760

Family Applications (4)

Application Number Title Priority Date Filing Date
ES13179055.2T Active ES2525029T3 (es) 2008-04-18 2009-04-17 Predicción del riesgo de sufrir episodios cardíacos adversos graves
ES09731842.2T Active ES2443125T3 (es) 2008-04-18 2009-04-17 Predicción del riesgo a sufrir episodios cardíacos adversos graves
ES16166093.1T Active ES2687401T3 (es) 2008-04-18 2009-04-17 Predicción del riesgo a sufrir episodios cardíacos adversos graves
ES14177846.4T Active ES2590213T3 (es) 2008-04-18 2009-04-17 Predicción del riesgo a sufrir episodios cardíacos adversos graves

Family Applications After (3)

Application Number Title Priority Date Filing Date
ES09731842.2T Active ES2443125T3 (es) 2008-04-18 2009-04-17 Predicción del riesgo a sufrir episodios cardíacos adversos graves
ES16166093.1T Active ES2687401T3 (es) 2008-04-18 2009-04-17 Predicción del riesgo a sufrir episodios cardíacos adversos graves
ES14177846.4T Active ES2590213T3 (es) 2008-04-18 2009-04-17 Predicción del riesgo a sufrir episodios cardíacos adversos graves

Country Status (13)

Country Link
US (5) US8090562B2 (cg-RX-API-DMAC10.html)
EP (5) EP2269063B1 (cg-RX-API-DMAC10.html)
JP (6) JP5526122B2 (cg-RX-API-DMAC10.html)
AU (3) AU2009236109B2 (cg-RX-API-DMAC10.html)
CA (1) CA2720674A1 (cg-RX-API-DMAC10.html)
DK (4) DK2660599T3 (cg-RX-API-DMAC10.html)
ES (4) ES2525029T3 (cg-RX-API-DMAC10.html)
HR (2) HRP20131100T1 (cg-RX-API-DMAC10.html)
HU (2) HUE029880T2 (cg-RX-API-DMAC10.html)
PL (4) PL3093663T3 (cg-RX-API-DMAC10.html)
PT (4) PT3093663T (cg-RX-API-DMAC10.html)
SI (4) SI2269063T1 (cg-RX-API-DMAC10.html)
WO (1) WO2009129454A2 (cg-RX-API-DMAC10.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
ES2375181T3 (es) 2002-05-09 2012-02-27 The Brigham And Women's Hospital, Inc. 1l 1rl-1 como un marcador de enfermedades cardiovasculares.
PL2386860T4 (pl) 2006-04-24 2015-09-30 Critical Care Diagnostics Inc Przewidywanie śmiertelności i wykrywanie poważnej choroby
ATE517341T1 (de) * 2006-04-27 2011-08-15 Critical Care Diagnostics Inc Interleukin-33 (il-33) zur diagnose und vorhersage von herz-gefäss-erkrankungen
DK2482078T3 (en) 2006-05-01 2016-05-02 Critical Care Diagnostics Inc Cardiovascular disease diagnosis
SI2019965T1 (sl) * 2006-05-02 2015-10-30 Critical Care Diagnostics, Inc. Diferencialna diagnoza med pljučno boleznijo in boleznijo srca in ožilja
US9968266B2 (en) 2006-12-27 2018-05-15 Cardiac Pacemakers, Inc. Risk stratification based heart failure detection algorithm
PT3093663T (pt) 2008-04-18 2018-10-19 Critical Care Diagnostics Inc Previsão do risco de eventos cardíacos adversos maiores
ES2795003T3 (es) * 2008-10-07 2020-11-20 Brahms Gmbh Biomarcador para la predicción de los primeros eventos adversos
US9561006B2 (en) * 2008-10-15 2017-02-07 The United States Of America As Represented By The Secretary Of The Navy Bayesian modeling of pre-transplant variables accurately predicts kidney graft survival
US8417541B1 (en) * 2009-08-27 2013-04-09 Cerner Innovation, Inc. Multi-stage model for predicting probabilities of mortality in adult critically ill patients
US20130066212A1 (en) * 2009-09-25 2013-03-14 Volcano Corporation Device and Method for Determining the Likelihood of a Patient Having a Clinical Event or a Clinically Silent Event Based on Ascertained Physiological Parameters
RU2684724C2 (ru) 2010-04-09 2019-04-11 Критикал Кэа Дайэгностикс, Инк. Антитела против растворимого st-2 человека и способы анализа
US10943676B2 (en) 2010-06-08 2021-03-09 Cerner Innovation, Inc. Healthcare information technology system for predicting or preventing readmissions
CN103718046B (zh) 2011-03-17 2016-10-12 重症监护诊断股份有限公司 预测不良临床结果的风险的方法
PL2734222T3 (pl) 2011-07-18 2017-03-31 Critical Care Diagnostics, Inc. Sposoby leczenia chorób układu krążenia i prognozowania skuteczności terapii ruchowej
EP2637023A1 (en) * 2012-03-08 2013-09-11 B.R.A.H.M.S GmbH Prediction of outcome in patients with chronic obstructive pulmonary disease
AU2013262515B2 (en) 2012-05-18 2018-03-15 Cardiac Pacemakers, Inc. Methods for treating or predicting risk of a ventricular tachyarrhythmia event
CN102830234A (zh) * 2012-08-10 2012-12-19 杭州华得森生物技术有限公司 一种检测人心力衰竭新型标志物st2的快速诊断试剂盒
MX358541B (es) 2012-08-16 2018-08-24 Critical Care Diagnostics Inc Metodos para predecir el riesgo de desarrollar hipertension.
IN2015DN01767A (cg-RX-API-DMAC10.html) 2012-08-21 2015-05-29 Critical Care Diagnostics Inc
RU2510505C1 (ru) * 2012-11-15 2014-03-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Тверская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ определения вероятности выраженной сердечной недостаточности в клинической картине инфаркта миокарда
GB201310290D0 (en) * 2013-06-10 2013-07-24 Univ Manchester Method for determining a probability of a major adverse cardiac event (MACE)
US20150199491A1 (en) * 2014-01-10 2015-07-16 Critical Care Diagnostics, Inc. Methods and systems for determining risk of heart failure
BR112017005730B1 (pt) 2014-09-26 2023-12-12 Somalogic Operating Co., Inc Método para triagem de um indivíduo quanto ao risco de um evento cardiovascular ou para predizer a probabilidade que um indivíduo tenha tal evento
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US20160256064A1 (en) * 2015-03-02 2016-09-08 Edward Harvey Estes, JR. Method and device to predict adverse cardiovascular events and mortality from an electrocardiogram-based validated risk score
US11576620B2 (en) * 2016-04-01 2023-02-14 Cardiac Pacemakers, Inc. Multi-disease patient management
AT518560B1 (de) 2016-04-18 2018-01-15 Trumpf Maschinen Austria Gmbh & Co Kg Biegebalken für eine Schwenkbiegemaschine
EP3614908B1 (en) 2017-04-29 2024-10-09 Cardiac Pacemakers, Inc. Heart failure event rate assessment
US20200074313A1 (en) * 2018-08-29 2020-03-05 Koninklijke Philips N.V. Determining features to be included in a risk assessment instrument
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
US12400762B2 (en) 2018-12-11 2025-08-26 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
US12322100B2 (en) 2018-12-11 2025-06-03 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity
EP3969620B1 (en) * 2019-05-17 2025-06-25 Regeneron Pharmaceuticals, Inc. Genome-based methods for reducing cardiovascular risk
US11551817B2 (en) 2020-01-14 2023-01-10 International Business Machines Corporation Assessing unreliability of clinical risk prediction
CN117099000A (zh) * 2021-03-08 2023-11-21 赛诺菲 心血管疾病
WO2023086746A1 (en) * 2021-11-11 2023-05-19 Beckman Coulter, Inc. Assessment of risk for major adverse cardiac event
US12553310B2 (en) 2023-09-07 2026-02-17 Halliburton Energy Services, Inc. Fire on demand barrier valve using wireless signal transmission and spring-forced piston

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
US5206140A (en) 1988-06-24 1993-04-27 Research Corporation Technologies, Inc. Assay for soluble crosslinked fibrin polymers
US5217899A (en) 1990-08-24 1993-06-08 The General Hospital Corporation Cell stretching apparatus
JP2665850B2 (ja) 1991-11-14 1997-10-22 塩野義製薬株式会社 ｈＢＮＰのＣ端を認識するモノクロ−ナル抗体
GB9211686D0 (en) 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
JP2732005B2 (ja) 1992-12-14 1998-03-25 眞一 富永 ヒトｓｔ２をコードするｄｎａ、該ｄｎａの発現産物、該ｄｎａを発現させることによる発現産物の製造方法
JPH0731479A (ja) 1993-02-23 1995-02-03 Shinichi Tominaga マウスｓｔ２ｌをコードするｄｎａ、該ｄｎａの発現産物、該ｄｎａを発現させることによる発現産物の製造方法
US6066322A (en) 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
AU7235296A (en) 1996-08-23 1998-03-06 Human Genome Sciences, Inc. T1 receptor-like ligand ii
CA2282401A1 (en) 1997-02-28 1998-09-03 Human Genome Sciences, Inc. T1/st2-receptor ligand iii
DE19711932A1 (de) 1997-03-21 1998-09-24 Anne Katrin Dr Werenskiold In vitro-Verfahren zum Prognostizieren des Krankheitsverlaufs von Patienten mit Mammakarzinom und/oder zum Diagnostizieren eines Mammakarzinoms
WO1998043630A1 (en) 1997-04-02 1998-10-08 Brigham And Women's Hospital, Inc. Means of ascertaining an individual's risk profile for atherosclerotic disease
US6210976B1 (en) 1997-06-10 2001-04-03 Medlyte Diagnostics, Inc. Methods for early detection of heart disease
AU731858B2 (en) 1997-09-11 2001-04-05 Shionogi & Co., Ltd. Immunoassay for BNP
GB9727172D0 (en) 1997-12-24 1998-02-25 Univ Glasgow Reagents specific for st2l and uses therefor
US6309888B1 (en) 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
GB9827348D0 (en) * 1998-12-12 1999-02-03 Univ Leicester Natriuretic peptide
AU2055300A (en) 1998-12-18 2000-07-03 Scios Inc. Methods for detection and use of differentially expressed genes in disease states
AU5309600A (en) 1999-06-02 2000-12-18 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of immune disorders
FR2795823B1 (fr) 1999-07-01 2001-11-23 Inst Nat Sante Rech Med Methodes et kits pour le diagnostic ou le suivi d'une pathologie synoviale ou osteoarticulaire comprenant l'utilisation d'un marqueur specifique de la degradation du tissu synovial
WO2001013900A2 (en) 1999-08-24 2001-03-01 Medicure International Inc. Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds
US6323334B1 (en) 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
WO2001070817A1 (en) 2000-03-21 2001-09-27 Medical & Biological Laboratories Co., Ltd. Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same
FR2807170B1 (fr) 2000-03-30 2002-06-28 Sipal Charniere elastique a frottement reduit
RU2002110275A (ru) 2000-08-22 2004-03-27 Дзе Брихэм Энд Уимен'З Хоспитал, Инк. (Us) Диагностика и лечение сердечно-сосудистых состояний
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
US6537221B2 (en) 2000-12-07 2003-03-25 Koninklijke Philips Electronics, N.V. Strain rate analysis in ultrasonic diagnostic images
FI20010019A7 (fi) 2001-01-05 2002-07-06 Biohit Oyj Menetelmä atrofisen gastriitin diagnostisoimiseksi
US20040253637A1 (en) 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
EP1322957B1 (en) 2001-05-04 2009-08-12 Biosite Incorporated Diagnostic markers of acute coronary syndromes and methods of use thereof
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
WO2003022987A2 (en) 2001-07-26 2003-03-20 Eos Biotechnology, Inc. Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection
US6810284B1 (en) 2001-11-21 2004-10-26 Pacesetter, Inc. Implantable cardiac stimulation system and method for monitoring diastolic function
ES2375181T3 (es) 2002-05-09 2012-02-27 The Brigham And Women's Hospital, Inc. 1l 1rl-1 como un marcador de enfermedades cardiovasculares.
WO2003100000A2 (en) 2002-05-24 2003-12-04 Tularik Inc. Amplification and overexpression of oncogenes
US8263325B2 (en) 2002-11-15 2012-09-11 Ottawa Heart Institute Research Corporation Predicting, detecting and monitoring treatment of cardiomyopathies and myocarditis
WO2004046729A2 (en) * 2002-11-21 2004-06-03 The University Of Leicester Bodily fluid markers of tissue hypoxia
AU2003299441A1 (en) 2002-12-19 2004-07-14 Centre National De La Recherche Scientifique - Cnrs Nf-hev compositions and methods of use
US20040133079A1 (en) 2003-01-02 2004-07-08 Mazar Scott Thomas System and method for predicting patient health within a patient management system
US20040220155A1 (en) 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
US20050123451A1 (en) 2003-10-31 2005-06-09 Hiroshi Nomura System and apparatus for body fluid analysis using surface-textured optical materials
EP1711622A2 (en) 2003-11-26 2006-10-18 Applera Corporation Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
AU2004296829A1 (en) 2003-12-05 2005-06-23 The Cleveland Clinic Foundation Risk markers for cardiovascular disease
US20050196817A1 (en) 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
JP2005291899A (ja) 2004-03-31 2005-10-20 Akira Matsumori 心疾患の検査法
WO2006066095A1 (en) 2004-12-17 2006-06-22 Clearwater Systems Corporation Method and apparatus for treating fluids
CA2595794A1 (en) 2005-01-24 2006-07-27 F. Hoffmann-La Roche Ag The use of cardiac hormones for assessing a cardiovascular risk with respect to the administration of anti-inflammatory drugs
EP1731910A1 (en) * 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases
US20070021977A1 (en) 2005-07-19 2007-01-25 Witt Biomedical Corporation Automated system for capturing and archiving information to verify medical necessity of performing medical procedure
JP4820192B2 (ja) 2006-03-17 2011-11-24 一般財団法人化学及血清療法研究所 急性冠症候群でのａｄａｍｔｓ１３の測定と利用
PL2386860T4 (pl) 2006-04-24 2015-09-30 Critical Care Diagnostics Inc Przewidywanie śmiertelności i wykrywanie poważnej choroby
ATE517341T1 (de) 2006-04-27 2011-08-15 Critical Care Diagnostics Inc Interleukin-33 (il-33) zur diagnose und vorhersage von herz-gefäss-erkrankungen
DK2482078T3 (en) * 2006-05-01 2016-05-02 Critical Care Diagnostics Inc Cardiovascular disease diagnosis
SI2019965T1 (sl) 2006-05-02 2015-10-30 Critical Care Diagnostics, Inc. Diferencialna diagnoza med pljučno boleznijo in boleznijo srca in ožilja
WO2007130627A2 (en) 2006-05-04 2007-11-15 The Brigham And Women's Hospital, Inc. Il-33 in the treatment and diagnosis of diseases and disorders
CA2659082A1 (en) * 2006-06-07 2007-12-21 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
RU2312591C1 (ru) 2006-06-14 2007-12-20 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Федерального агентства по здравоохранению и социальному развитию" Способ прогнозирования развития риска внезапной смерти у больных с лево- и правожелудочковой экстрасистолией
WO2008116083A1 (en) 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
JP2010526555A (ja) 2007-05-11 2010-08-05 タフツ・メディカル・センター 加齢関連黄斑変性と関係するポリヌクレオチド及び患者のリスクを評価する方法
GB0713404D0 (en) 2007-07-11 2007-08-22 Integra Sp Ipr Ltd Altio graph
WO2009040133A1 (en) 2007-09-26 2009-04-02 Universitätsklinikum Heidelberg Osteopontin as novel prognostic biomarker for heart failure
FR2923029B1 (fr) 2007-10-26 2009-11-20 Minima Lunettes de type sans entourage a branches filaires
PT3093663T (pt) 2008-04-18 2018-10-19 Critical Care Diagnostics Inc Previsão do risco de eventos cardíacos adversos maiores
WO2010025393A2 (en) * 2008-08-28 2010-03-04 The Regents Of The University Of California Protein biomarkers and methods for diagnosing kawasaki disease
US20100159474A1 (en) 2008-11-11 2010-06-24 B.R.A.H.M.S. Aktiengesellschaft Prognosis and risk assessment in patients suffering from heart failure by determining the level of adm and bnp
EP2568294B1 (en) 2009-11-13 2015-01-07 BG Medicine, Inc. Risk Factors and Prediction of Myocardial Infaraction
US8258456B2 (en) 2009-11-27 2012-09-04 Himax Imaging, Inc. Image sensor
RU2684724C2 (ru) 2010-04-09 2019-04-11 Критикал Кэа Дайэгностикс, Инк. Антитела против растворимого st-2 человека и способы анализа
RU2017110678A (ru) 2010-11-01 2019-01-24 Б.Р.А.Х.М.С Гмбх Оценка прогноза и риска пациентов с неспецифическими жалобами
RU2452394C1 (ru) 2010-11-09 2012-06-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Ульяновский государственный университет Способ прогнозирования риска смерти больных хронической сердечной недостаточностью
CN103718046B (zh) 2011-03-17 2016-10-12 重症监护诊断股份有限公司 预测不良临床结果的风险的方法
US8615387B2 (en) * 2011-04-07 2013-12-24 Invensys Systems, Inc. Dynamic simulation of fluid filled vessels
PL2734222T3 (pl) 2011-07-18 2017-03-31 Critical Care Diagnostics, Inc. Sposoby leczenia chorób układu krążenia i prognozowania skuteczności terapii ruchowej
AU2013262515B2 (en) 2012-05-18 2018-03-15 Cardiac Pacemakers, Inc. Methods for treating or predicting risk of a ventricular tachyarrhythmia event
MX358541B (es) * 2012-08-16 2018-08-24 Critical Care Diagnostics Inc Metodos para predecir el riesgo de desarrollar hipertension.
IN2015DN01767A (cg-RX-API-DMAC10.html) * 2012-08-21 2015-05-29 Critical Care Diagnostics Inc
US9665593B2 (en) * 2013-03-28 2017-05-30 International Business Machines Corporation Dynamically synching elements in file
JP6178687B2 (ja) 2013-09-27 2017-08-09 富士機械工業株式会社 グラビア塗工装置
US20150199491A1 (en) 2014-01-10 2015-07-16 Critical Care Diagnostics, Inc. Methods and systems for determining risk of heart failure
USD770057S1 (en) 2014-04-14 2016-10-25 Critical Care Diagnostics, Inc. Blood test kit
US9934249B2 (en) 2014-06-03 2018-04-03 Conduent Business Machines Services, Llc Systems and methods for context-aware and personalized access to visualizations of road events
USD800332S1 (en) 2014-09-23 2017-10-17 Critical Care Diagnostics, Inc. Blood test kit
USD800333S1 (en) 2014-09-23 2017-10-17 Critical Care Diagnostics, Inc. Blood test kit
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker

Also Published As

Publication number Publication date
EP2269063A2 (en) 2011-01-05
PL2660599T3 (pl) 2015-03-31
HUE039963T2 (hu) 2019-02-28
US20130244236A1 (en) 2013-09-19
EP3378955A1 (en) 2018-09-26
SI2827152T1 (sl) 2016-10-28
PL2827152T3 (pl) 2016-12-30
HRP20131100T1 (hr) 2014-01-31
JP6788050B2 (ja) 2020-11-18
US8090562B2 (en) 2012-01-03
AU2009236109B2 (en) 2015-11-05
CA2720674A1 (en) 2009-10-22
EP2269063B1 (en) 2013-08-21
HUE029880T2 (en) 2017-04-28
SI2660599T1 (sl) 2014-12-31
EP2827152A1 (en) 2015-01-21
WO2009129454A2 (en) 2009-10-22
EP2660599B1 (en) 2014-09-10
JP6484679B2 (ja) 2019-03-13
ES2590213T3 (es) 2016-11-18
WO2009129454A3 (en) 2010-01-28
JP2021039108A (ja) 2021-03-11
PT2827152T (pt) 2016-09-13
HK1152750A1 (en) 2012-03-09
PT2660599E (pt) 2014-11-28
US20150081224A1 (en) 2015-03-19
JP2017203784A (ja) 2017-11-16
US20120065897A1 (en) 2012-03-15
EP3093663B1 (en) 2018-06-13
US9965593B2 (en) 2018-05-08
DK2269063T3 (da) 2013-12-02
JP2014178322A (ja) 2014-09-25
JP2019105645A (ja) 2019-06-27
AU2016200697A1 (en) 2016-02-25
HK1185658A1 (en) 2014-02-21
AU2018202350A1 (en) 2018-04-26
JP5873521B2 (ja) 2016-03-01
HK1206419A1 (en) 2016-01-08
EP2660599A1 (en) 2013-11-06
SI3093663T1 (sl) 2018-10-30
PT2269063E (pt) 2013-11-27
US11170896B2 (en) 2021-11-09
ES2687401T3 (es) 2018-10-25
EP3093663A1 (en) 2016-11-16
ES2443125T3 (es) 2014-02-17
PT3093663T (pt) 2018-10-19
AU2009236109A1 (en) 2009-10-22
EP2827152B1 (en) 2016-06-08
JP6200975B2 (ja) 2017-09-20
DK2827152T3 (en) 2016-09-12
JP2011520098A (ja) 2011-07-14
PL3093663T3 (pl) 2018-11-30
US9886553B2 (en) 2018-02-06
EP2269063A4 (en) 2011-05-04
DK3093663T3 (en) 2018-09-24
US20090264779A1 (en) 2009-10-22
AU2016200697B2 (en) 2018-01-04
DK2660599T3 (en) 2014-12-08
SI2269063T1 (sl) 2014-01-31
JP5526122B2 (ja) 2014-06-18
JP2016048272A (ja) 2016-04-07
HRP20141056T1 (hr) 2015-01-02
US20180233229A1 (en) 2018-08-16
PL2269063T3 (pl) 2014-04-30

Similar Documents

Publication Publication Date Title
ES2443125T3 (es) Predicción del riesgo a sufrir episodios cardíacos adversos graves
Puls et al. Failure of acute procedural success predicts adverse outcome after percutaneous edge-to-edge mitral valve repair with MitraClip
Kelley et al. Increases of cardiac troponin in conditions other than acute coronary syndrome and heart failure
Thielmann et al. ESC Joint Working Groups on Cardiovascular Surgery and the Cellular Biology of the Heart Position Paper: Peri-operative myocardial injury and infarction in patients undergoing coronary artery bypass graft surgery
Hallbergson et al. Right ventricular remodeling after pulmonary valve replacement: early gains, late losses
Canty et al. Hibernating myocardium
Schuster et al. Fast manual long-axis strain assessment provides optimized cardiovascular event prediction following myocardial infarction
ES2440740T3 (es) Utilización de SLIM-1 en la evaluación de la insuficiencia cardiaca
Castillo et al. Brain natriuretic peptide: a potential marker for mortality in septic shock
Seoudy et al. HFA-PEFF score: prognosis in patients with preserved ejection fraction after transcatheter aortic valve implantation
Stähli et al. N‐terminal pro‐B‐type natriuretic peptide‐ratio predicts mortality after transcatheter aortic valve replacement
Thoker et al. Correlation of cardiac troponin I levels with infective endocarditis & its adverse clinical outcomes
Reader et al. Left ventricular hypertrophy in rhesus macaques (Macaca mulatta) at the California National Primate Research Center (1992–2014)
Abbate et al. Right ventricular cardiomyocyte apoptosis in patients with acute myocardial infarction of the left ventricular wall
Bäck et al. Biomarkers in mitral regurgitation
Benza et al. Risk assessment in pulmonary arterial hypertension patients: the long and short of it
Reza et al. From hypertrophy to heart failure: what is new in genetic cardiomyopathies
Penela et al. Identification of the potentially arrhythmogenic substrate in the acute phase of ST-segment elevation myocardial infarction
Alhadid et al. The study of Triple-Dip La Nina phenomenon (2020-2023) and its impact on atmospheric dynamics and rainfall in the Indonesian region
Baruteau et al. Peripartum cardiomyopathy in the era of cardiac magnetic resonance imaging: first results and perspectives
Lim et al. Detected troponin elevation is associated with high early mortality after lung resection for cancer
Cho et al. Prognostic value of left atrial volume index in patients with rheumatic mitral stenosis
McCarthy Trip and mode choice decisions to out-patient health care facilities: A longitudinal analysis
Palmrich et al. Prognostic value of maternal N‐terminal pro‐B‐type natriuretic peptide for prediction of severe maternal adverse outcome in women with pre‐eclampsia
Park et al. Impact of climate change on species distribution of Picea jezoensis Carrière in Baekdudaegan using ensemble modeling